Clinical Trial

EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T

Study acronym: VIOLET
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated April 6, 2025 (before its estimated August 3, 2025 completion). Its status may not reflect the trial's current state.
Summary
This clinical trial will evaluate the safety and efficacy of \[161Tb\]Tb -PSMA-I\&T in men with metastatic castration-resistant prostate cancer (mCRPC).
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-08-26; most recent amendment 2025-04-03.
Status change: Active, Not Recruiting → Recruiting 2025-04-03
Status change: Recruiting → Active, Not Recruiting 2024-03-14
Status change: Not Yet Recruiting → Recruiting 2022-10-06
Trial Details
NCT Number NCT05521412
Lead Sponsor Peter MacCallum Cancer Centre, Australia
Conditions Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Enrollment 42 participants
Start Date 2022-09-29
Primary Completion 2025-08-03 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-04-06